{"id":33477,"date":"2025-05-15T12:40:33","date_gmt":"2025-05-15T04:40:33","guid":{"rendered":"https:\/\/flcube.com\/?p=33477"},"modified":"2025-05-15T12:40:34","modified_gmt":"2025-05-15T04:40:34","slug":"roches-ventana-met-sp44-rxdx-assay-gains-fda-approval-for-nsq-nsclc-patients","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33477","title":{"rendered":"Roche&#8217;s VENTANA MET (SP44) RxDx Assay Gains FDA Approval for NSQ-NSCLC Patients"},"content":{"rendered":"\n<p>Swiss giant Roche (<a href=\"https:\/\/www.google.com\/finance\/quote\/ROG:SWX\">SWX: ROG<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/RHHBY:OTCMKTS\">OTCMKTS: RHHBY<\/a>) announced that the FDA has approved the VENTANA\u00ae MET (SP44) RxDx Assay, a groundbreaking companion diagnostic for non-squamous non-small cell lung cancer (NSQ-NSCLC). This approval marks a significant step forward in personalised healthcare, enabling the identification of patients who may benefit from AbbVie\u2019s c-Met-targeted therapy Emrelis\u2122 (telisotuzumab vedotin-tllv).<\/p>\n\n\n\n<p><strong>The MET Protein: A Key Biomarker<\/strong><br>The VENTANA MET (SP44) RxDx Assay detects the MET protein, which is over-expressed in some patients with NSQ-NSCLC. This protein serves as a predictive biomarker for the likelihood of a patient\u2019s response to c-Met-targeted therapy. Among advanced NSCLC patients with a normal (wild-type) epidermal growth factor receptor (EGFR) gene, around a quarter exhibit high levels of MET protein, making it a crucial factor in determining treatment options.<\/p>\n\n\n\n<p><strong>Roche&#8217;s Leadership in Companion Diagnostics<\/strong><br>As the leader in companion diagnostics, Roche\u2019s broad CDx portfolio helps enable informed clinical decisions and improved patient outcomes. The launch of the VENTANA MET (SP44) RxDx Assay exemplifies Roche\u2019s commitment to advancing personalised healthcare and represents an important addition to the company\u2019s market-leading portfolio of immunohistochemistry (IHC) and in situ hybridisation (ISH) companion diagnostics.<\/p>\n\n\n\n<p><strong>Clinical Data Supporting FDA Approval<\/strong><br>The FDA accelerated approval is supported by data from the Phase 2 LUMINOSITY study, an ongoing study designed to characterise the efficacy and safety of Emrelis in c-Met overexpressing advanced NSQ-NSCLC populations. Findings from the study showed patients with c-Met protein high expression who received Emrelis demonstrated a 35% overall response rate (ORR) and duration of response (DoR) with a median of 7.2 months.<\/p>\n\n\n\n<p><strong>About the VENTANA MET (SP44) RxDx Assay<\/strong><br>The VENTANA MET (SP44) RxDx Assay detects the MET protein and is scored by pathologists based on the percentage of tumour cells stained and the intensity of the staining. MET protein overexpression is defined as \u226550% tumor cells demonstrating strong (3+) membrane and\/or cytoplasmic staining. By providing critical information on MET protein expression, the assay informs clinicians about the likelihood that a patient will benefit from c-Met-targeted therapy, allowing for a more personalised approach to treating NSQ-NSCLC.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that the FDA has approved the VENTANA\u00ae&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33478,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[940,15,163,939],"class_list":["post-33477","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-medical-device","tag-otcmkts-rhhby","tag-product-approvals","tag-roche","tag-swx-rop"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Roche&#039;s VENTANA MET (SP44) RxDx Assay Gains FDA Approval for NSQ-NSCLC Patients - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that the FDA has approved the VENTANA\u00ae MET (SP44) RxDx Assay, a groundbreaking companion diagnostic for non-squamous non-small cell lung cancer (NSQ-NSCLC). This approval marks a significant step forward in personalised healthcare, enabling the identification of patients who may benefit from AbbVie\u2019s c-Met-targeted therapy Emrelis\u2122 (telisotuzumab vedotin-tllv).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33477\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche&#039;s VENTANA MET (SP44) RxDx Assay Gains FDA Approval for NSQ-NSCLC Patients\" \/>\n<meta property=\"og:description\" content=\"Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that the FDA has approved the VENTANA\u00ae MET (SP44) RxDx Assay, a groundbreaking companion diagnostic for non-squamous non-small cell lung cancer (NSQ-NSCLC). This approval marks a significant step forward in personalised healthcare, enabling the identification of patients who may benefit from AbbVie\u2019s c-Met-targeted therapy Emrelis\u2122 (telisotuzumab vedotin-tllv).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33477\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-15T04:40:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-15T04:40:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1503.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33477#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33477\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Roche&#8217;s VENTANA MET (SP44) RxDx Assay Gains FDA Approval for NSQ-NSCLC Patients\",\"datePublished\":\"2025-05-15T04:40:33+00:00\",\"dateModified\":\"2025-05-15T04:40:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33477\"},\"wordCount\":360,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33477#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1503.webp\",\"keywords\":[\"OTCMKTS: RHHBY\",\"Product approvals\",\"Roche\",\"SWX: ROP\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33477#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33477\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33477\",\"name\":\"Roche's VENTANA MET (SP44) RxDx Assay Gains FDA Approval for NSQ-NSCLC Patients - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33477#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33477#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1503.webp\",\"datePublished\":\"2025-05-15T04:40:33+00:00\",\"dateModified\":\"2025-05-15T04:40:34+00:00\",\"description\":\"Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that the FDA has approved the VENTANA\u00ae MET (SP44) RxDx Assay, a groundbreaking companion diagnostic for non-squamous non-small cell lung cancer (NSQ-NSCLC). This approval marks a significant step forward in personalised healthcare, enabling the identification of patients who may benefit from AbbVie\u2019s c-Met-targeted therapy Emrelis\u2122 (telisotuzumab vedotin-tllv).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33477#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33477\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33477#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1503.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1503.webp\",\"width\":1080,\"height\":608,\"caption\":\"Roche's VENTANA MET (SP44) RxDx Assay Gains FDA Approval for NSQ-NSCLC Patients\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33477#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Roche&#8217;s VENTANA MET (SP44) RxDx Assay Gains FDA Approval for NSQ-NSCLC Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Roche's VENTANA MET (SP44) RxDx Assay Gains FDA Approval for NSQ-NSCLC Patients - Insight, China&#039;s Pharmaceutical Industry","description":"Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that the FDA has approved the VENTANA\u00ae MET (SP44) RxDx Assay, a groundbreaking companion diagnostic for non-squamous non-small cell lung cancer (NSQ-NSCLC). This approval marks a significant step forward in personalised healthcare, enabling the identification of patients who may benefit from AbbVie\u2019s c-Met-targeted therapy Emrelis\u2122 (telisotuzumab vedotin-tllv).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33477","og_locale":"en_US","og_type":"article","og_title":"Roche's VENTANA MET (SP44) RxDx Assay Gains FDA Approval for NSQ-NSCLC Patients","og_description":"Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that the FDA has approved the VENTANA\u00ae MET (SP44) RxDx Assay, a groundbreaking companion diagnostic for non-squamous non-small cell lung cancer (NSQ-NSCLC). This approval marks a significant step forward in personalised healthcare, enabling the identification of patients who may benefit from AbbVie\u2019s c-Met-targeted therapy Emrelis\u2122 (telisotuzumab vedotin-tllv).","og_url":"https:\/\/flcube.com\/?p=33477","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-15T04:40:33+00:00","article_modified_time":"2025-05-15T04:40:34+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1503.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33477#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33477"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Roche&#8217;s VENTANA MET (SP44) RxDx Assay Gains FDA Approval for NSQ-NSCLC Patients","datePublished":"2025-05-15T04:40:33+00:00","dateModified":"2025-05-15T04:40:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33477"},"wordCount":360,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33477#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1503.webp","keywords":["OTCMKTS: RHHBY","Product approvals","Roche","SWX: ROP"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33477#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33477","url":"https:\/\/flcube.com\/?p=33477","name":"Roche's VENTANA MET (SP44) RxDx Assay Gains FDA Approval for NSQ-NSCLC Patients - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33477#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33477#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1503.webp","datePublished":"2025-05-15T04:40:33+00:00","dateModified":"2025-05-15T04:40:34+00:00","description":"Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that the FDA has approved the VENTANA\u00ae MET (SP44) RxDx Assay, a groundbreaking companion diagnostic for non-squamous non-small cell lung cancer (NSQ-NSCLC). This approval marks a significant step forward in personalised healthcare, enabling the identification of patients who may benefit from AbbVie\u2019s c-Met-targeted therapy Emrelis\u2122 (telisotuzumab vedotin-tllv).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33477#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33477"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33477#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1503.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1503.webp","width":1080,"height":608,"caption":"Roche's VENTANA MET (SP44) RxDx Assay Gains FDA Approval for NSQ-NSCLC Patients"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33477#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Roche&#8217;s VENTANA MET (SP44) RxDx Assay Gains FDA Approval for NSQ-NSCLC Patients"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1503.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33477","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33477"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33477\/revisions"}],"predecessor-version":[{"id":33479,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33477\/revisions\/33479"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33478"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33477"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33477"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}